Texas Liver Institute - Academic Profile

Publications

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi , Vlad Ratziu , Rohit Loomba +97 more

2019 The Lancet 1142 citations

Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide

Husam Albarmawi , Firas Dabbous , Abdalla Aly +5 more

In patients with MASH and either overweight or obesity, semaglutide was associated with a clinically and statistically significant reduction in ALT after 6 months of continuous ...

2025 Current Medical Research and Opinion 0 citations

Affiliated Researchers

Eric Lawitz

Texas Liver Institute

Institution Info

Type: healthcare
Country: US
Publications: 2
Citations: 1,142

External Links

Identifiers

ROR: https://ror.org/03yk6x532